 |
|
|
Press Releases
MERGE EFILM ANNOUNCES AVAILABILITY
OF MERGECOM-3™ ADVANCED INTEGRATOR'S TOOL KIT TRIAL
VERSION ON WEBSITE
Trial software delivers full functionality for 30 days;
provides developers with hands-on experience with the
DICOM development software used by more than 200 software
development corporations throughout the world.
Milwaukee, WI, April 22, 2003 - Merge eFilm (Nasdaq:
MRGE), a leading global PACS provider and foremost in
DICOM development, today announced that its MergeCOM-3™
Advanced Integrator's Tool Kit software is now conveniently
available for a free 30 day trial as a downloadable
file from the Merge eFilm website (www.merge.com).
MergeCOM-3 is a cross-platform, scalable DICOM implementation
tool set for medical imaging application developers.
MergeCOM-3 greatly reduces the time to bring DICOM conformant
products to the medical imaging market by enabling developers
to focus on their product application rather than the
low level details of the DICOM protocol. MergeCOM-3
is highly configurable to best support the needs of
many different development environments, from UNIX and
embedded operating systems to DOS, LINUX, Windows, Java
and Macintosh. Over 200 companies have been using MergeCOM-3
for the past eight years in the development of their
radiology and information system products.
Stuart Swerdloff, PhD, Medical Physicist at Philips
Medical Systems, began utilizing MergeCOM-3 eight years
ago, and is currently using it for development of its
Nuclear Medicine products. "MergeCOM-3 has provided
a significant advantage, allowing us to assure DICOM
capabilities and accelerate the development time of
our solutions," said Dr. Swerdloff. " In addition,
the service level of Merge eFilm's Toolkit Support Team
has been outstanding - a very important factor for our
developers. Good Product, Good Company, Great People.
They've all evolved, but those qualities haven't changed
since the last time I said it five years ago."
Richard Linden, Merge's President and CEO said, "We
continue to invest in the evolution of our products,
particularly those that lead the market like our MergeCOM-3
toolkit. Providing a trial version is representative
of our confidence that MergeCOM-3 is the best value
in DICOM toolkits in the market today, and we are pleased
to provide our customers with the ability to determine
its value prior to their purchase."
***
Merge eFilm provides integrated healthcare image and
information workflow solutions that create a filmless
workflow environment, address the clinical imaging needs
across the healthcare enterprise, and enable cost-effective,
patient-centric care. For more than fifteen years, Merge eFilm has leveraged its healthcare IT, clinical and
engineering experience to create elegant and affordable
solutions that improve the clinicians' productivity
and enhance the quality of the care they provide. For
additional information, go to www.merge.com.
|
Attn: Beth Frost-Johnson
Merge Healthcare
6737 West Washington St.
Suite 2250
Milwaukee, WI 53214
|
|
|
|
|
|
| Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, the forward-looking statements based on a number of factors, including, but not limited to, the uncertainty created by, the adverse impact on relationships with customers, potential customers, suppliers and investors potentially resulting from, and other risks associated with, the changes in the Company’s senior management; costs, risks and effects of the investigation by the Audit Committee of the Board of Directors; the impact of the restatement of financial statements of the Company and other actions that may be taken or required as a result of such restatement; the Company's inability to timely file reports with the Securities and Exchange Commission; risks associated with the Company's inability to meet the requirements of The NASDAQ Stock Market for continued listing, including possible delisting; costs, risks and effects of legal proceedings and investigations, including the informal, non-public inquiry being conducted by the Securities and Exchange Commission and class action, derivative, and other lawsuits; risks in product and technology development, market acceptance of new products and continuing product demand, the impact of competitive products and pricing, ability to integrate acquisitions, changing economic conditions, credit and payment risks associated with end-user sales, dependence on major customers, dependence on key personnel, and other risk factors detailed in the Company’s filings with the Securities and Exchange Commission. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements contained herein to reflect future events, developments, or changed circumstances, or for any other reason.
|
|
|
